Gene therapy for neurodegenerative and ocular diseases using lentiviral vectors

Clinical Science

Volumn 110, Issue 1, 2006, Pages 37-46

  Ralph, G Scott ^a   Binley, Katie ^a   Wong, Liang Fong ^a   Azzouz, Mimoun ^a   Mazarakis, Nicholas D ^a  

^a OXFORD BIOMEDICA UK LTD   (United Kingdom)

Author keywords

Gene transfer; Interfering RNA (RNAi); Lentivirus; Neurodegeneration; Ocular disease; Retinal disorder; Viral vector

Indexed keywords

LENTIVIRUS VECTOR;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CELL POPULATION; DEGENERATIVE DISEASE; EYE DISEASE; GENE EXPRESSION; GENE SILENCING; GENE THERAPY; HUMAN; HUNTINGTON CHOREA; MITOSIS; NERVE CELL; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RETINA DEGENERATION; REVIEW; TRANSGENE; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; EYE DISEASES; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; LENTIVIRUS; NEURODEGENERATIVE DISEASES; RETINAL DEGENERATION;

EID: 30344463007     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20050158     Document Type: Review

References (124)

1. Relph, K., Harrington, K. and Pandha, H. (2004) Recent developments and current status of gene therapy using viral vectors in the United Kingdom. Br. Med. J. 329, 839-842
2. Cao, H., Koehler, D. R. and Hu, J. (2004) Adenoviral vectors for gene replacement therapy. Viral Immunol. 17, 327-333
3. Volpers, C. and Kochanek, S. (2004) Adenoviral vectors for gene transfer and therapy. J. Gene Med. 6 (Suppl. 1), S164-S171
4. Schagen, F. H., Ossevoort, M., Toes, R. E. and Hoeben, R. C. (2004) Immune responses against adenoviral vectors and their transgene products: a review of strategies for evasion. Crit. Rev. Oncol. Hematol. 50, 51-70
5. Thomas, C. E., Birkett, D., Anozie, I., Castro, M. G. and Lowenstein, P. R. (2001) Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain. Mol. Ther. 3, 36-46
6. Lehrman, S. (1999) Virus treatment questioned after gene therapy death. Nature 401, 517-518
7. Sakhuja, K., Reddy, P. S., Ganesh, S. et al. (2003) Optimization of the generation and propagation of gutless adenoviral vectors. Hum. Gene Ther. 14, 243-254
8. Kochanek, S., Schiedner, G. and Volpers, C. (2001) High-capacity 'gutless' adenoviral vectors. Curr. Opin. Mol. Ther. 3, 454-463
9. McKelvey, T., Tang, A., Bett, A. J., Casimiro, D. R. and Chastain, M. (2004) T-cell response to adenovirus hexon and DNA-binding protein in mice. Gene Ther. 11, 791-796
10. Liu, Q. and Muruve, D. A. (2003) Molecular basis of the inflammatory response to adenovirus vectors. Gene Ther. 10, 935-940
11. Tenenbaum, L., Chtarto, A., Lehtonen, E., Velu, T., Brotchi, J. and Levivier, M. (2004) Recombinant AAV-mediated gene delivery to the central nervous system. J Gene Med. 6 (Suppl. 1), S212-S222
12. Lu, Y. (2004) Recombinant adeno-associated virus as delivery vector for gene therapy: a review. Stem Cells Dev. 13, 133-145
13. Kaplitt, M. G., Leone, P., Samulski, R. J. et al. (1994) Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat. Genet. 8, 148-154
14. McCarty, D. M., Young, Jr, S. M. and Samulski, R. J. (2004) Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu. Rev. Genet. 38, 819-845
15. Nakai, H., Storm, T. A. and Kay, M. A. (2000) Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors. Nat. Biotechnol. 18, 527-532
16. Duan, D., Yue, Y., Yan, Z. and Engelhardt, J. F. (2000) A new dual-vector approach to enhance recombinant adeno-associated virus-mediated gene expression through intermolecular as activation. Nat. Med. 6, 595-598
17. Sun, L., Li, J. and Xiao, X. (2000) Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization. Nat. Med. 6, 599-602
18. Kay, M. A., Manno, C. S., Ragni, M. V. et al. (2000) Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat. Genet. 24, 257-261
19. Nakai, H., Montini, E., Fuess, S., Storm, T. A., Grompe, M. and Kay, M. A. (2003) AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat. Genet. 34, 297-302
20. Kay, M. A. and Nakai, H. (2003) Looking into the safety of AAV vectors. Nature (London) 424, 251
21. Luo, J., Kaplitt, M. G., Fitzsimons, H. L. et al. (2002) Subthalamic GAD gene therapy in a Parkinson's disease rat model. Science 298, 425-429
22. During, M. J., Kaplitt, M. G., Stern, M. B. and Eidelberg, D. (2001) Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation. Hum. Gene Ther. 12, 1589-1591
23. Betchen, S. A. and Kaplitt, M. (2003) Future and current surgical therapies in Parkinson's disease. Curr. Opin. Neurol. 16, 487-493
24. Glorioso, J. C. and Fink, D. J. (2004) Herpes vector-mediated gene transfer in treatment of diseases of the nervous system. Annu. Rev. Microbiol. 58, 253-271
25. Post, D. E., Fulci, G., Chiocca, E. A. and Van Meir, E. G. (2004) Replicative oncolytic herpes simplex viruses in combination cancer therapies. Curr. Gene Ther. 4, 41-51
26. Shah, A. C., Benos, D., Gillespie, G. Y. and Markert, J. M. (2003) Oncolytic viruses: clinical applications as vectors for the treatment of malignant ghomas. J. Neurooncol. 65, 203-226
27. Lever, A. M., Strappe, P. M. and Zhao, J. (2004) Lentiviral vectors. J. Biomed. Sci. 11, 439-449
28. Martin-Rendon, E., Azzouz, M. and Mazarakis, N. D. (2001) Lentiviral vectors for the treatment of neurodegenerative diseases. Curr. Opin. Mol. Ther. 3, 476-481
29. Azzouz, M., Kingsman, S. M. and Mazarakis, N. D. (2004) Lentiviral vectors for treating and modeling human CNS disorders. J. Gene Med. 6, 951-962
30. Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M. et al. (2003) LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-Xl. Science 302, 415-419
31. Naldini, L., Blomer, U., Gallay, P. et al. (1996) In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272, 263-267
32. Dull, T., Zufferey, R., Kelly, M. et al. (1998) A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72, 8463-8471
33. Kim, V. N., Mitrophanous, K., Kingsman, S. M. and Kingsman, A. J. (1998) Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1. J. Virol. 72, 811-816
34. Kotsopoulou, E., Kim, V. N., Kingsman, A. J., Kingsman, S. M. and Mitrophanous, K. A. (2000) A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene. J. Virol. 74, 4839-4852
35. Rohll, J. B., Mitrophanous, K. A., Martin-Rendon, E. et al. (2002) Design, production, safety, evaluation and clinical applications of nonprimate lentiviral vectors. Methods Enzymol. 346, 466-500
36. Mitrophanous, K., Yoon, S., Rohll, J. et al. (1999) Stable gene transfer to the nervous system using a non-primate lentiviral vector. Gene Ther. 6, 1808-1818
37. Poeschla, E. M., Wong-Staal, F. and Looney, D. J. (1998) Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors. Nat. Med. 4, 354-357
38. Mazarakis, N. D., Azzouz, M., Rohll, J. B. et al. (2001) Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery. Hum. Mol. Genet. 10, 2109-2121
39. Wong, L. F., Azzouz, M., Walmsley, L. E. et al. (2004) Transduction patterns of pseudotyped lentiviral vectors in the nervous system. Mol. Ther. 9, 101-111
40. Azzouz, M., Ralph, G. S., Storkebaum, E. et al. (2004) VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature (London) 429, 413-417
41. Sirin, O. and Park, F. (2003) Regulating gene expression using self-inactivating lentiviral vectors containing the mifepristone-inducible system. Gene 323, 67-77
42. Reiser, J., Lai, Z., Zhang, X. Y. and Brady, R. O. (2000) Development of multigene and regulated lentivirus vectors. J. Virol. 74, 10589-10599
43. Pluta, K., Luce, M. J., Bao, L., Agha-Mohammadi, S. and Reiser, J. (2005) Tight control of transgene expression by lentivirus vectors containing second-generation tetracycline-responsive promoters. J. Gene Med. 7, 803-817
44. Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A. and Evans, D. A. (2004) State-specific projections through 2025 of Alzheimer disease prevalence. Neurology 62, 1645
45. Hardy, J. and Allsop, D. (1991) Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci. 12, 383-388
46. Hardy, J. and Selkoe, D. J. (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356
47. Selkoe, D. J. (1991) The molecular pathology of Alzheimer's disease. Neuron 6, 487-498
48. Haass, C., Schlossmacher, M. G., Hung, A. Y. et al. (1992) Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature (London) 359, 322-325
49. Glenner, G. G. and Wong, C. W. (1984) Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120, 885-890
50. Kang, J., Lemaire, H. G., Unterbeck, A. et al. (1987) The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature (London) 325, 733-736
51. Roberds, S. L., Anderson, J., Basi, G. et al. (2001) BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum. Mol. Genet. 10, 1317-1324
52. Xia, H., Mao, Q., Paulson, H. L. and Davidson, B. L. (2002) siRNA-mediated gene silencing in vitro and in vivo. Nat. Biotechnol. 20, 1006-1010
53. Miller, V. M., Xia, H., Marrs, G. L. et al. (2003) Allele-specific silencing of dominant disease genes. Proc. Natl. Acad. Sci. U.S.A. 100, 7195-7200
54. Ralph, G. S., Radcliffe, P. A., Day, D. M. et al. (2005) Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat. Med. 11, 429-433
55. Kao, S. C., Krichevsky, A. M., Kosik, K. S. and Tsai, L. H. (2004) BACE1 suppression by RNA interference in primary cortical neurons. J. Biol. Chem. 279, 1942-1949
56. Iwata, N., Tsubuki, S., Takaki, Y. et al. (2000) Identification of the major Aβ1-Aβ42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat. Med. 6, 143-150
57. Iwata, N., Tsubuki, S., Takaki, Y. et al. (2001) Metabolic regulation of brain Aβ by neprilysin. Science 292, 1550-1552
58. Marr, R. A., Guan, H., Rockenstein, E. et al. (2004) Neprilysin regulates amyloid Beta peptide levels. J. Mol. Neurosci. 22, 5-11
59. Marr, R. A., Rockenstein, E., Mukherjee, A. et al. (2003) Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J. Neurosci. 23, 1992-1996
60. Dawbarn, D., Allen, S. J. and Semenenko, F. M. (1988) Coexistence of choline acetyltransferase and nerve growth factor receptors in the rat basal forebrain. Neurosci. Lett. 94, 138-144
61. Holtzman, D. M., Li, Y., Parada, L. F. et al. (1992) p140trk mRNA marks NGF-responsive forebrain neurons: evidence that trk gene expression is induced by NGF. Neuron 9, 465-478
62. Kiss, J., McGovern, J. and Patel, A. J. (1988) Immunohistochemical localization of cells containing nerve growth factor receptors in the different regions of the adult rat forebrain. Neuroscience 27, 731-748
63. Tuszynski, M. H., U, H. S., Alksne, J. et al. (2002) Growth factor gene therapy for Alzheimer disease. Neurosurg. Focus 13, e5
64. Eriksdotter Jonhagen, M., Nordberg, A., Amberla, K. et al. (1998) Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 9, 246-257
65. Rosenberg, M. B., Friedmann, T., Robertson, R. C. et al. (1988) Grafting genetically modified cells to the damaged brain: restorative effects of NGF expression. Science 242, 1575-1578
66. Conner, J. M., Darracq, M. A., Roberts, J. and Tuszynski, M. H. (2001) Nontropic actions of neurotrophins: subcortical nerve growth factor gene delivery reverses age-related degeneration of primate cortical cholinergic innervation. Proc. Natl. Acad. Sci. U.S.A. 98, 1941-1946
67. Smith, D. E., Roberts, J., Gage, F. H. and Tuszynski, M. H. (1999) Age-associated neuronal atrophy occurs in the primate brain and is reversible by growth factor gene therapy. Proc. Natl. Acad. Sci. U.S.A. 96, 10893-10898
68. Tuszynski, M. H., Roberts, J., Senut, M. C., U, H. S. and Gage, F. H. (1996) Gene therapy in the adult primate brain: intraparenchymal grafts of cells genetically modified to produce nerve growth factor prevent cholinergic neuronal degeneration. Gene Ther. 3, 305-314
69. Mandel, R. J., Gage, F. H., Clevenger, D. G., Spratt, S. K., Snyder, R. O. and Leff, S. E. (1999) Nerve growth factor expressed in the medial septum following in vivo gene delivery using a recombinant adeno-associated viral vector protects cholinergic neurons from fimbria-fornix lesion-induced degeneration. Exp. Neurol. 155, 59-64
70. Blomer, U., Kafri, T., Randolph-Moore, L., Verma, I. M. and Gage, F. H. (1998) Bcl-xL protects adult septal cholinergic neurons from axotomized cell death. Proc. Natl. Acad. Sci. U.S.A. 95, 2603-2608
71. Tuszynski, M. H., Thal, L., Pay, M. et al. (2005) A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat. Med. 11, 551-555
72. McKeith, I. G. and Mosimann, U. P. (2004) Dementia with Lewy bodies and Parkinson's disease. Parkinsonism Relat. Disord. 10 (Suppl. 1), S15-S18
73. Mouradian, M. M. (2002) Recent advances in the genetics and pathogenesis of Parkinson disease. Neurology 58, 179-185
74. Paisan-Ruiz, C., Jain, S., Evans, E. W. et al. (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44, 595-600
75. Zimprich, A., Biskup, S., Leitner, P. et al. (2004) Mutations in LRRK2 cause autosomal-dominant Parkinsonism with pleomorphic pathology. Neuron 44, 601-607
76. Bossy-Wetzel, E., Schwarzenbacher, R. and Lipton, S. A. (2004) Molecular pathways to neurodegeneration. Nat. Med. 10 (Suppl.), S2-S9
77. Kirik, D., Georgievska, B. and Bjorklund, A. (2004) Localized striatal delivery of GDNF as a treatment for Parkinson disease. Nat. Neurosci. 7, 105-110
78. Gill, S. S., Patel, N. K., Hotton, G. R. et al. (2003) Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 9, 589-595
79. Deglon, N., Tseng, J. L., Bensadoun, J. C. et al. (2000) Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease. Hum. Gene Ther. 11, 179-190
80. Bensadoun, J. C., Deglon, N., Tseng, J. L., Ridet, J. L., Zurn, A. D. and Aebischer, P. (2000) Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF. Exp. Neurol. 164, 15-24
81. Azzouz, M., Ralph, S., Wong, L. F. et al. (2004) Neuroprotection in a rat Parkinson model by GDNF gene therapy using EIAV vector. NeuroReport 15, 985-990
82. Georgievska, B., Kirik, D., Rosenblad, C., Lundberg, C. and Bjorklund, A. (2002) Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector. NeuroReport 13, 75-82
83. Lo Bianco, C., Deglon, N., Pralong, W. and Aebischer, P. (2004) Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease. Neurobiol. Dis. 17, 283-289
84. Kordower, J. H., Emborg, M. E., Bloch, J. et al. (2000) Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290, 767-773
85. Georgievska, B., Kirik, D. and Bjorklund, A. (2002) Aberrant sprouting and downregulation of tyrosme hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer. Exp. Neurol. 177, 461-474
86. Georgievska, B., Jakobsson, J., Persson, E., Ericson, C., Kirik, D. and Lundberg, C. (2004) Regulated delivery of glial cell line-derived neurotrophic factor into rat striatum, using a tetracycline-dependent lentiviral vector. Hum. Gene Ther. 15, 934-944
87. Azzouz, M., Martin-Rendon, E., Barber, R. D. et al. (2002) Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic L-amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat model of Parkinson's disease. J. Neurosci. 22, 10302-10312
88. Bankiewicz, K. S., Eberling, J. L., Kohutnicka, M. et al. (2000) Convection-enhanced delivery of AAV vector in parkinsonian monkeys: in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp. Neurol. 164, 2-14
89. Sanchez-Pernaute, R., Harvey-White, J., Cunningham, J. and Bankiewicz, K. S. (2001) Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats. Mol. Ther. 4, 324-330
90. Muramatsu, S., Fujimoto, K., Ikeguchi, K. et al. (2002) Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes. Hum. Gene Ther. 13, 345-354
91. Sun, M., Kong, L., Wang, X. et al. (2004) Coexpression of tyrosine hydroxylase, GTP cyclohydrolase I, aromatic amino acid decarboxylase, and vesicular monoamine transporter 2 from a helper virus-free herpes simplex virus type 1 vector supports high-level, long-term biochemical and behavioral correction of a rat model of Parkinson's disease. Hum. Gene Ther. 15, 1177-1196
92. de Almeida, L. P., Zala, D., Aebischer, P. and Deglon, N. (2001) Neuroprotective effect of a CNTF-expressing lentiviral vector in the quinolinic acid rat model of Huntington's disease. Neurobiol. Dis. 8, 433-446
93. Keils, A. P., Fong, D. M., Dragunow, M., During, M. J., Young, D. and Connor, B. (2004) AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington disease. Mol. Ther. 9, 682-688
94. Handley, O. J., Naji, J., Dunnett, S. B. and Rosser, A. E. (2006) Pharmaceutical, cellular and genetic therapies for Huntington's disease. Clin. Sci. 110, 73-88
95. Chen, Z. J., Kren, B. T., Wong, P. Y., Low, W. C. and Steer, C. J. (2005) Sleeping Beauty-mediated down-regulation of huntingtin expression by RNA interference. Biochem. Biophys. Res. Commun. 329, 646-652
96. Xia, H., Mao, Q., Eliason, S. L. et al. (2004) RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat. Med. 10, 816-820
97. Harper, S. Q., Staber, P. D., He, X. et al. (2005) RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc. Natl. Acad. Sci. U.S.A. 102, 5820-5825
98. Gurney, M. E., Pu, H., Chiu, A. Y. et al. (1994) Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264, 1772-1775
99. Bruijn, L. I., Becher, M. W., Lee, M. K. et al. (1997) ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 18, 327-338
100. Dal Canto, M. C. and Gurney, M. E. (1995) Neuropathological changes in two lines of mice carrying a transgene for mutant human Cu,Zn SOD, and in mice overexpressing wild type human SOD: a model of familial amyotrophic lateral sclerosis (FALS). Brain Res. 676, 25-40
101. Kaspar, B. K., Llado, J., Sherkat, N., Rothstein, J. D. and Gage, F. H. (2003) Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 301, 839-842
102. Raoul, C., Abbas-Terki, T., Bensadoun, J. C. et al. (2005) Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat. Med. 11, 423-428
103. Rahmani, B., Tielsch, J. M., Katz, J. et al. (1996) The cause-specific prevalence of visual impairment in an urban population. The Baltimore Eye Survey. Ophthalmology 103, 1721-1726
104. Aiello, L. P., Avery, R. L., Arrigg, P. G. et al. (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 331, 1480-1487
105. Pe'er, J., Shweiki, D., Itin, A., Hemo, I., Gnessin, H. and Keshet, E. (1995) Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab. Invest. 72, 638-645
106. Ohno-Matsui, K., Hirose, A., Yamamoto, S. et al. (2002) Inducible expression of vascular endothelial growth factor in adult mice causes severe proliferative retinopathy and retinal detachment. Am. J. Pathol. 160, 711-719
107. Takahashi, K., Saishin, Y., Silva, R. L. et al. (2003) Intraocular expression of endostatin reduces VEGF-induced retinal vascular permeability, neovascularization, and retinal detachment. FASEB J. 17, 896-898
108. Miyoshi, H., Takahashi, M., Gage, F. H. and Verma, I. M. (1997) Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. Proc. Natl. Acad. Sci. U.S.A. 94, 10319-10323
109. Ikeda, Y., Goto, Y., Yonemitsu, Y. et al. (2003) Simian immunodeficiency virus-based lentivirus vector for retinal gene transfer: a preclinical safety study in adult rats. Gene Ther. 10, 1161-1169
110. Takahashi, K., Luo, T., Saishin, Y. et al. (2002) Sustained transduction of ocular cells with a bovine immunodeficiency viral vector. Hum. Gene Ther. 13, 1305-1316
111. Lotery, A. J., Derksen, T. A., Russell, S. R. et al. (2002) Gene transfer to the nonhuman primate retina with recombinant feline immunodeficiency virus vectors. Hum. Gene Ther. 13, 689-696
112. Cheng, L., Toyoguchi, M., Looney, D. J., Lee, J., Davidson, M. C. and Freeman, W. R. (2005) Efficient gene transfer to retinal pigment epithelium cells with long-term expression. Retina 25, 193-201
113. Loewen, N., Leske, D. A., Cameron, J. D. et al. (2004) Long-term retinal transgene expression with FIV versus adenoviral vectors. Mol. Vis. 10, 272-280
114. Pagon, R. A. (1988) Retinitis pigmemosa. Surv. Ophthalmol. 33, 137-177
115. Miyazaki, M., Ikeda, Y., Yonemitsu, Y. et al. (2003) Simian lentiviral vector-mediated retinal gene transfer of pigment epithelium-derived factor protects retinal degeneration and electrical defect in Royal College of Surgeons rats. Gene Ther. 10, 1503-1511
116. Duisit, G., Conrath, H., Saleun, S. et al. (2002) Five recombinant simian immunodeficiency virus pseudotypes lead to exclusive transduction of retinal pigmented epithelium in rat. Mol. Ther. 6, 446-454
117. Auricchio, A., Kobinger, G., Anand, V. et al. (2001) Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: the retina as a model. Hum. Mol. Genet. 10, 3075-3081
118. Takahashi, M., Miyoshi, H., Verma, I. M. and Gage, F. H. (1999) Rescue from photoreceptor degeneration in the rd mouse by human immunodeficiency virus vector-mediated gene transfer. J. Virol. 73, 7812-7816
119. Loewen, N., Leske, D. A., Chen, Y. et al. (2003) Comparison of wild-type and class I integrase mutant-FIV vectors in retina demonstrates sustained expression of integrated transgenes in retinal pigment epithelium. J. Gene Med. 5, 1009-1017
120. Loewen, N., Fautsch, M. P., Peretz, M. et al. (2001) Genetic modification of human trabecular meshwork with lentiviral vectors. Hum. Gene Ther. 12, 2109-2119
121. Loewen, N., Fautsch, M. P., Teo, W. L., Bahler, C. K., Johnson, D. H. and Poeschla, E. M. (2004) Long-term, targeted genetic modification of the aqueous humor outflow tract coupled with noninvasive imaging of gene expression in vivo. Invest. Ophthalmol. Vis. Sci. 45, 3091-3098
122. Bainbridge, J. W., Stephens, C., Parsley, K. et al. (2001) In vivo gene transfer to the mouse eye using an HIV-based lentiviral vector; efficient long-term transduction of corneal endothelium and retinal pigment epithelium. Gene Ther. 8, 1665-1668
123. Wang, X., Appukuttan, B., Ott, S. et al. (2000) Efficient and sustained transgene expression in human corneal cells mediated by a lentiviral vector. Gene Ther. 7, 196-200
124. Wilson, S. E. and Bourne, W. M. (1988) Fuchs' dystrophy. Cornea 7, 2-18